Yelena Shames on Pausing Immunotherapy for Laboratory Abnormalities
Yelena Shames, MSA, ACNP-BC, CNRN, discusses when immune checkpoint inhibitor treatment should be paused because of laboratory abnormalities.
Ridad and McKaig Discuss Oncology Nurse Perceptions on Medical Cannabis
Improvements in Health Systems Model Reduces Disparities in Leukemia Survival in Low-Income Countries
Telephone and Web-Based Program Elicits Clinically Meaningful Results in Breast Cancer Survivors
Luspatercept Elicits High Transfusion Independence Rates in Lower-Risk MDS
